Eli Lilly Blood-Brain Barrier Delivery Platform

Eli Lilly Blood-Brain Barrier Delivery Platform

Overview

Eli Lilly Blood-Brain Barrier Delivery Platform

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Eli Lilly Blood-Brain Barrier Delivery Platform</th>
</tr>
<tr>
<td class="label">Modification</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">FcRn engagement</td>
<td>Extended half-life</td>
</tr>
<tr>
<td class="label">FcgammaR reduction</td>
<td>Minimized effector function</td>
</tr>
<tr>
<td class="label">Affinity maturation</td>
<td>Enhanced target binding</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">TRAILBLAZER-ALZ</td>
<td>10 mg/kg Q4W</td>
</tr>
<tr>
<td class="label">TRAILBLAZER-ALZ</td>
<td>10 mg/kg Q4W</td>
</tr>
<tr>
<td class="label">TRAILBLAZER-ALZ 2</td>
<td>10 mg/kg Q4W</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Donanemab</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Abeta plaques</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>IV infusion</td>
</tr>
<tr>
<td class="label">Brain penetration</td>
<td>Enhanced</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Abeta plaques</td>
</tr>
<tr>
<td class="label">Remternetug</td>
<td>pE3-Abeta</td>
</tr>
<tr>
<td class="label">LY3886406</td>
<td>[Tau](/proteins/tau)</td>
</tr>
<tr>
<td class="label">Undisclosed</td>
<td>alpha-syn</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Primary Approach</td>
</tr>
<tr>
<td class="label">Eli Lilly</td>
<td>Fc engineering + RMT</td>
</tr>
<tr>
<td class="label">Roche/Genentech</td>
<td>TfR bispecific</td>
</tr>
<tr>
<td class="label">Biogen/Lundbeck</td>
<td>Antibody engineering</td>
</tr>
<tr>
<td class="label">J&J</td>
<td>RMT platform</td>
</tr>
</table>

Eli Lilly has developed a comprehensive multi-modal [blood-brain barrier](/entities/blood-brain-barrier) (BBB) delivery platform to enhance central nervous system (CNS) penetration of therapeutic antibodies for Alzheimer's disease and other neurodegenerative disorders. The platform combines advanced Fc engineering, receptor-mediated transcytosis (RMT) strategies, and combination approaches with emerging technologies like focused ultrasound [1].

Eli Lilly's BBB delivery efforts have been particularly successful with their amyloid-targeting programs. [Donanemab](/entities/donanemab) (Kisunla), their anti-amyloid antibody, demonstrates significantly higher brain plaque clearance than competitor antibodies at comparable doses, suggesting superior brain penetration. The company is building on this success with next-generation programs including Remternetug and other pipeline assets [2].

Multi-Modal CNS Delivery Approach

Eli Lilly employs a multi-pronged strategy to overcome the BBB:

1. Fc Engineering

Lilly has developed proprietary Fc engineering to optimize brain delivery:

The Fc modifications enable lower dosing while maintaining therapeutic efficacy, reducing both cost and potential side effects [3].

2. Receptor-Mediated Transcytosis

Lilly is developing RMT-targeted antibodies:

• Transferrin receptor (TfR) targeting: Engineer antibodies to bind TfR and cross the BBB
• Insulin receptor modulation: Explore alternative RMT pathways
• Novel transporter identification: Research new brain delivery targets [4]

3. Focused Ultrasound Combination

Partnerships with focused ultrasound companies:

• Temporary BBB opening: Enable enhanced antibody delivery
• Localized treatment: Target specific brain regions
• Dose reduction potential: Achieve efficacy with lower antibody doses [5]

Donanemab (Kisunla) — Brain Exposure Data

Donanemab has demonstrated remarkable plaque clearance in clinical trials:

Clinical Trial Results

Brain Penetration Advantages

Donanemab's superior efficacy is attributed to:

• High brain exposure: Achieves significant plaque clearance at lower doses than competitors
• Plaque binding affinity: High-affinity binding to [Aβ](/proteins/amyloid-beta) plaques in brain tissue
• Sustained delivery: Extended half-life enables consistent brain exposure [6]

Remternetug — Next-Generation Program

Remternetug (formerly LY3372993) is Eli Lilly's next-generation anti-amyloid antibody:

Mechanism

• Target: N-terminal pyroglutamate Aβ (pE3-Aβ)
• Format: IgG1 antibody with engineered Fc
• Delivery: Optimized for enhanced brain penetration [7]

Clinical Status

Remternetug is currently in clinical development for early Alzheimer's disease:

• Phase 1: Completed (demonstrated safety and brain amyloid reduction)
• Phase 2: Ongoing
• Phase 3: Planning

Advantages Over Donanemab

Pipeline Programs

Eli Lilly's BBB delivery platform supports multiple CNS programs:

Alzheimer's Disease

Other CNS Indications

• Parkinson's disease: [α-synuclein](/proteins/alpha-synuclein) targeting
• ALS: Multiple targets under investigation
• Depression: Rapid-acting antidepressants

Focused Ultrasound Partnerships

Eli Lilly has explored combinations with focused ultrasound technology:

Collaboration Approach

• Temporary BBB opening: Enable enhanced delivery of large molecules
• Regional targeting: Focus treatment on affected brain regions
• Dose sparing: Reduce required antibody doses [8]

Potential Benefits

Comparison with Industry

BBB Delivery Approaches

Eli Lilly's approach balances high brain exposure with established manufacturing and regulatory pathways.

Key Publications

See Also

• [Eli Lilly](/companies/eli-lilly)
• [Donanemab (Kisunla)](/therapeutics/donanemab)
• [Remternetug](/entities/remternetug)
• [Anti-Amyloid Therapeutics](/mechanisms/anti-amyloid-therapeutics)
• [Brain Shuttle Technologies](/technologies/brain-shuttles)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
• [TRAILBLAZER-ALZ 2 Trial](/clinical-trials/donanemab-trailblazer-alz2)
• [Focused Ultrasound for BBB Opening](/therapeutics/focused-ultrasound-bbb-opening)

External Links

• [Eli Lilly Alzheimer's Pipeline](https://www.lilly.com)
• [Kisunla (Donanemab) Product Information](https://kisanla.com)
• [ClinicalTrials.gov](https://clinicaltrials.gov)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery](/hypothesis/h-d78123d1) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: RAB27A/LAMP2B
• [Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring](/hypothesis/h-e23f05fb) — <span style="color:#ffd54f;font-weight:600">0.42</span> · Target: Disease-causing mutations with integrated reporters
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Gut Barrier Permeability-α-Synuclein Axis Modulation](/hypothesis/h-6c83282d) — <span style="color:#ffd54f;font-weight:600">0.60</span> · Target: CLDN1, OCLN, ZO1, MLCK
• [RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo delivery](/hypothesis/h-250b34ab) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: RAB27A
• [Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery](/hypothesis/h-346639e8) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: TRAK1_KIF5A
• [Mitochondrial SPM Synthesis Platform Engineering](/hypothesis/h-13bbfdc5) — <span style="color:#ffd54f;font-weight:600">0.47</span> · Target: ALOX5

Related Analyses:

• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Mitochondrial transfer between neurons and glia](/analysis/SDA-2026-04-01-gap-20260401231108) &#x1f504;
• [Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) &#x1f504;